Eton Pharmaceuticals Inc., an innovative pharmaceutical company focusing on treatments for rare diseases, has announced U.S. FDA approval for its New Drug Application (NDA) for KHINDIVI™ (hydrocortisone) Oral Solution. This marks the first and only FDA-approved hydrocortisone oral solution, designed as a replacement therapy for pediatric patients aged five years and older with adrenocortical insufficiency. The commercial launch is anticipated the week of June 2nd. This approval represents a significant advancement for families dealing with pediatric congenital adrenal hyperplasia $(CAH)$, offering a more accurate dosing option than previously available. Eton expects peak combined sales of KHINDIVI and ALKINDI SPRINKLE® to exceed $50 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.